Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing psilocybin for PTSD

This pilot study will examine the safety, tolerability, acceptability, and how well it works of combination psilocybin + psychotherapy to decrease PTSD symptoms. you would be randomly assigned into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.

Official registry: https://clinicaltrials.gov/study/NCT07332143 · Emory University · enrollment listed as 150

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are psilocybin, Supportive Therapy, or Prolonged Exposure Therapy. The registry lists allocation as randomized. This pilot study will examine the safety, tolerability, acceptability, and how well it works of combination psilocybin + psychotherapy to decrease PTSD symptoms.

They plan to enroll about 150 people at Atlanta. Taking part typically means taking a study drug (or dummy pill), following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD

Interventions: psilocybin, Supportive Therapy, Prolonged Exposure Therapy

Primary outcome (registry wording): Change in PTSD symptoms based on CAPS-5-R total severity score

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Meet criteria for PTSD due to trauma occurring at least 3 months prior based on CAPS-5-R diagnostic scoring rules
  • Able to speak and read English (due to standardization of outcome measures)
  • Willingness of participant to sign a release for the investigators to communicate with their primary care or mental health providers, if indicated
  • Are 18 years and older
  • Are able to swallow pills
  • Agree to have study visits video and/or audio recorded, including Medicine Session, Independent Rater assessments, and non-drug psychotherapy sessions
  • Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable

Public study contact (from the registry)

Anna Wise, PhD

404-712-1035

patstudy@emory.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: real iTBS for Mild Traumatic Brain Injury

This study will determine (i) the magnitude of immediate and sustained effects of a current clinical standard interactive computer attention processing training (APT) when combined with intermittent theta burst stimulation (iTBS), a type of repetitive transcranial magnetic stimulation and (ii) determine how APT + iTBS changes the neurocognitive system of attention in individuals with persistent attention deficits related to mTBI +/- PTSD.

NCT03819608 · Official ClinicalTrials.gov record · Northwestern University

RecruitingNot a traditional drug phaseRichmond, Virginia
Not a traditional drug phase: Antioxidant for Peripheral Vascular Diseases

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

FAQ about this NCT record

Is NCT07332143 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07332143?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07332143?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary